Christopher Molineaux, President & CEO, Life Sciences PA

In an interview with Invest:, Christopher Molineaux, president and CEO of Life Sciences Pennsylvania, shared key trends shaping the life sciences sector, from mRNA technologies to cell and gene therapy. “We’re going to see the launch of new companies, in addition to the continued growth of existing companies in the region,” said Molineaux.

What have been some recent changes for Life Sciences Pennsylvania and the industry as a whole?

The last two to three years have been very challenging for small companies raising capital. Investors have been sitting on the sidelines largely because of public policy issues, creating a degree of uncertainty for the industry and business in general. That’s not unique to life sciences, and certainly not unique to Pennsylvania.

Having said that, we are encouraged by our 940 member companies at Life Sciences Pennsylvania, with leaders very accustomed to solving the most complicated problems. These are people who get up every day to solve unmet medical needs. There are still thousands of diseases affecting millions of patients around the world who are waiting for scientists to do their jobs and come up with solutions. So, the industry continues to grow and succeed, and by extension, Life Sciences Pennsylvania has grown, even in this stormy environment. Life Sciences Pennsylvania has been seen as a calm port, and we have brought in more than 350 new members in the last three years.

What policies and legislation changes have you been monitoring closely?

Gov. Josh Shapiro is dedicating a lot of energy and resources to the life sciences. The industry is seeing this incredible level of support for the first time in 25 years. Being from Montgomery County, he understands the strong value, the economic impact, and the jobs created by the life sciences community in the county. He’s taken that vision statewide, proposing $50 million for an innovation fund from his annual budget, including $30 million specifically dedicated to life sciences. We are welcoming this initiative and are advocating strongly with the General Assembly to get that proposal over the finish line.

What makes Montgomery County a great location for businesses in the life sciences industry?

I would have to start with talent. The talent for life sciences in Montgomery County is unmatched anywhere in the world. That might sound a little over the top, but when you think about the history of Montgomery County and Pennsylvania, it is home to major global pharmaceutical companies. Companies like Johnson & Johnson, Merck, Pfizer, and GSK have been in this region for decades, but even before that, some of their founders went to school in Philadelphia. Those companies then become a school, if you will, for future leaders at new companies. 

Montgomery County also has geographical benefits. We sit almost equidistant between two very important stakeholder groups: the capital markets of New York and the regulatory bodies in Washington, D.C., that affect our industry, like the Food and Drug Administration and the National Institutes of Health. Additionally, the cost of living in Montgomery County, compared to other life sciences hubs in the country, is very desirable.

What are the main challenges facing the life sciences sector?

It all comes down to the financial situation, and there are multiple components to it. Over the last two to three years, raising capital to run a company has been difficult because of policies coming out of Washington, D.C. Then, it was policies that were shaping reimbursement. Now, the conversations around tariffs and the executive orders coming out of the White House create more uncertainties for an industry that is already very difficult to navigate.

Nine out of 10 biopharmaceutical companies that are developing, trying to launch, and going through the FDA approval process for a pharmaceutical product will fail. These processes are very high-stakes and expensive. Starting from its initial submission at the FDA, it takes on average 12 years for a drug to get approval, with an average cost of $2.6 billion. Keeping in mind that nine out of 10 will fail, many may only get halfway through that process and spend $500 million as sunk costs. So, investors are already very cautious. When you add another layer of uncertainty, like federal policy, that makes investors even more reluctant to fund this high-risk business. 

Which areas of collaboration would mitigate some of these challenges?

Our mission in dealing with the federal government now is to minimize uncertainty as much as we can and get explanations for the policies that might not be very clear. As an advocacy organization, we spend a lot of time in Washington, D.C., educating policymakers about the risks and the unintended consequences of their actions. It’s an ongoing dialogue — these conversations didn’t just start in 2025, or even in the last three years.

This is what we have been doing as an organization for 35 years: educating lawmakers at the federal and state levels. At the state level, we are feeling very positive about what the Shapiro administration is doing. On top of the innovation fund, the Shapiro administration is going to continue funding the Ben Franklin Technology Partners and the Life Sciences Greenhouse, which are seed capital organizations, as well as research and development tax credits, and other various incentives. When you stack those up, it’s about a $100 million commitment that would benefit our industry. 

Which sectors within life sciences hold the most potential to drive growth in the region over the next decade?

There’s a category referred to as advanced therapeutics. This could include mRNA technologies, cell therapy, and gene therapy. Southeast Pennsylvania is a hub of cell and gene therapy development. Franklin Biolabs, for example, is a Contract Development and Manufacturing Organization (CDMO) helping to manufacture cell and gene therapies for organizations that are ready to scale up production. There is Krystal Biotech, a company that has a technology to home-manufacture cell therapy. Their product was approved in 2023, making it the first topical cell-based therapeutic ever approved by the FDA. Cell and gene therapy continues to be hot, and the number of organizations making the manufacturing of those therapeutics possible is growing.

What are the major trends for the region’s life sciences sector?

We’re going to see the launch of new companies, in addition to the continued growth of existing companies in the region. Pennsylvania, Philadelphia, and Montgomery County are getting greater visibility from the outside world, being recognized as areas of growth and opportunity for all the reasons I mentioned earlier.

New employment opportunities and the spotlight on this region are drawing talent at all levels. In addition to existing talent, we are attracting talent from outside of the region, and even from outside of the state, to run companies in southeastern Pennsylvania. Among our 940 member companies, 585 are in southeastern Pennsylvania, including Montgomery County, Chester County, Bucks County, Delaware County, and Philadelphia County.